respiratory syncytial virus

News

Moderna swings to loss as COVID sales slump

Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin

News

GSK grabs early lead in RSV vaccine race with Pfizer

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f

News

GSK targets younger age group with RSV jab Arexvy

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s

News

CDC backs maternal use of Pfizer’s RSV vaccine

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor

News

Moderna looks to its post-COVID growth prospects

With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ

News

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower r

Moderna swings to loss as COVID sales slump

GSK grabs early lead in RSV vaccine race with Pfizer

GSK targets younger age group with RSV jab Arexvy

CDC backs maternal use of Pfizer’s RSV vaccine

Moderna looks to its post-COVID growth prospects

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

respiratory syncytial virus

Editor's Picks